Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., . . . Kagamu, H. (2019). Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Wiley.
Chicago-stil citatYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
MLA-referensYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.